ERBB2 and breast cancer: Trastuzumab is the first HER2 antibody which displayed a remarkable improvement of OS in HER2-positive patients with BC [57], but the large molecular weight (about 148 kDa) precludes the penetration of the intact BBB, leading the CNS to be the most frequent site of relapse [12,58].